 Home > Active Ingredient News > Antitumor Therapy > The world’s first ADC drug targeting CD19, Loncastuximab tesirine, launched a key phase II study, and completed the first patient administration in a clinical trial in China

The world’s first ADC drug targeting CD19, Loncastuximab tesirine, launched a key phase II study, and completed the first patient administration in a clinical trial in China

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

oxygen enter cell

phase locked loop

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

2021 Nian 9 Yue 29 days, by the way Ling Pharmaceutical and ADC Therapeutics creation of a joint venture Ling Luaidisi announced, carried out in China Loncastuximab tesirine for relapsed / diffuse large refractory B cell lymphoma ( r / r DLBCL ) A pivotal phase II clinical trial of the company completed the first patient dosing

2021 Nian 9 Yue 29 days, by the way Ling Pharmaceutical and ADC Therapeutics creation of a joint venture Ling Luaidisi announced, carried out in China Loncastuximab tesirine for relapsed / refractory diffuse large B cell lymphoma ( lymphoma r / r DLBCL ) in a pivotal phase II clinical trial completed the first patient dosing

This year 4 months, Loncastuximab tesirine access to the US Food and Drug Administration Administration ( Administration the FDA the FDA ) accelerated approval, becoming the first and only one targeting CD19 antibody drug conjugate ( the ADC ) drugs for at least monotherapy Adult patients with r/r DLBCL who have received 2- line or higher system therapy .

Diffuse large B- cell lymphoma ( DLBCL ) is the most common type of adult lymphoma, a malignant tumor with great heterogeneity in clinical manifestations and prognosis

ADC Therapeutics CEO Chris Martin Dr.

Loncastuximab tesirine is an antibody-conjugated drug ( ADC ) targeting CD19 .

The U.

Xu Jianen, CEO of Linglu Idis, said: " Completing the first patient dosing of this key clinical trial is an important milestone
.
At the same time, we always hope to work with our partners to expand the clinical practice of Loncastuximab tesirine in Greater China and Singapore.
Scope of application
.
At present, many patients in China are suffering from r/r DLBCL .
We will, as always, strive to meet the unfulfilled needs of patients and provide effective ADC drugs to
patients around the world who lack appropriate treatment methods .
We look forward to and ADC Therapeutics jointly realizes the continuous development and commercialization of
Loncastuximab tesirine in Asia .
"

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.